The Nippon India Nifty Pharma ETF has recorded a 19.9% gain over the last six months, ranking as a top performer among index-based funds. While the returns highlight strength in the pharmaceutical sector, investors should note the specific concentration risks associated with sector-focused funds compared to broader market indices.
The Nippon India Nifty Pharma ETF (PHARMABEES) has delivered a return of 19.9% over the past six months, outperforming many peer index funds. This performance, recorded as of mid-August 2026, reflects the broader momentum seen within the pharmaceutical sector, as the ETF specifically tracks the Nifty Pharma Index.
Unlike diversified index funds that invest across various industries, this ETF is restricted to pharmaceutical companies. This structure means the fund’s performance is directly tied to the health and growth of the pharma sector rather than the wider economy. Its portfolio includes major industry players such as Sun Pharma, Divi's Lab, and Cipla. Because the fund is heavily concentrated in these specific stocks, its value can move significantly based on sector-specific news, regulatory approvals, and drug pricing trends.
Beyond the six-month performance, the fund has shown steady results across other timeframes. Data as of August 2026 shows consistent gains over one-month, three-month, and three-year periods, often outpacing the benchmark index. The fund currently manages assets worth approximately ₹1,691.41 crore and operates with an expense ratio of 0.21%. For index funds, the expense ratio is a key factor, as it represents the cost an investor pays to hold the fund, directly impacting the final returns.
While the recent performance is strong, investors should be aware of the specific risks involved with this type of investment. The primary risk is concentration. Because the fund does not diversify into sectors like IT, banking, or infrastructure, it is vulnerable to downturns specific to the pharma industry. If the sector faces pricing pressure or negative regulatory changes, the fund may see a steeper decline than a diversified index fund.
Additionally, there is a risk known as tracking error. This occurs when the ETF’s returns deviate slightly from the actual Nifty Pharma Index due to factors like management fees, cash holdings, and trading expenses. While these differences are often small, they are inherent to how ETFs function.
Looking ahead, the fund’s ability to maintain its performance will depend on the continued growth and stability of the pharmaceutical companies within its index. Investors tracking this fund may watch for updates on the sector’s regulatory environment, export demand, and the financial health of the top pharma companies, as these factors will drive the underlying index and, consequently, the ETF.